Immunization and Vaccines for Children
Agency: Centers for Disease Control - NCIRD
- 93.268 -- Immunization Cooperative Agreements
Archived opportunityLast Updated: May 13, 2026
View version history on Grants.gov
Description
The National Center for Immunization and Respiratory Diseases (NCIRD) is committed to the prevention of disease, disability, and death through immunization and by the control of respiratory and related diseases. NCIRD protects individuals and communities from vaccine-preventable disease through provision of federal funds and contracts to purchase and distribute vaccine, provision of technical and financial support of immunization programs, vaccine preventable disease surveillance, provider and public education, and evaluation.This cooperative agreement will support recipients with development, implementation, assessment, and promotion of immunization related activities with the goal of achieving and sustaining high immunization coverage, and with administration of the Vaccines for Children (VFC) and Section 317 vaccine program for eligible individuals and to maintain or improve response activities to vaccine preventable disease public health threats.
Eligibility
Eligible applicants
Government
- Special district governments
- City or township governments
- State governments
Miscellaneous
- Other
Additional information
Grantor contact information
Description
Grants Policy
Documents
| File name | Description | Last updated |
|---|---|---|
| CDC-RFA-19-1901_UPDATE_4.20.2020_A_FINAL_002.pdf | CDC-RFA-IP19-1901 Final | Apr 20, 2020 07:04 PM UTC |
Link to additional information
--
Archived: June 4, 2020
Award
$377,277,423
Program Funding
64
Expected awards
$--
Award Minimum
$--
Award Maximum
Funding opportunity number:
CDC-RFA-IP19-1901
Cost sharing or matching requirement:
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
Category of Funding Activity:
Health
Category Explanation:
History
Version:
5
Posted date:
February 5, 2019
Archive date:
June 4, 2020
